A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

NCT07332533 | Not Yet Recruiting Phase 2 DMC

• 1 other identifier: KN026-006
• Study Type: interventional
• Target: 490
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer.

Conditions

HER2-positive Gastric Cancer

Outcome Measures

Primary Outcomes (2)

• Objective Response Rate (ORR) by investigator in Phase II

  Up to approximately 5 years

• Progression-Free Survival (PFS) by BIRC in Phase III

  Up to approximately 5 years

Secondary Outcomes (1)

• Overall Survival (OS) in Phase III

  Up to approximately 5 years

Study Arms (4)

Group A：Combination of KN026 and CAPOX/PF with or without enlonstobart

EXPERIMENTAL

Drug: KN026; Drug: Capecitabine; Drug: Enlonstobart; Drug: Oxaliplatin; Drug: Cisplatin; Drug: Fluorouracil

Group B: Combination of trastuzumab, and CAPOX/PF with or without enlonstobart

EXPERIMENTAL

Drug: Capecitabine; Drug: Enlonstobart; Drug: Oxaliplatin; Drug: Trastuzumab; Drug: Cisplatin; Drug: Fluorouracil

Experimental group: Combination of KN026 and CAPOX/PF with or without enlonstobart

EXPERIMENTAL

Drug: KN026; Drug: Capecitabine; Drug: Enlonstobart; Drug: Oxaliplatin; Drug: Cisplatin; Drug: Fluorouracil

Control group：Combination of trastuzumab and CAPOX/PF with or without Pembrolizumab

EXPERIMENTAL

Drug: Capecitabine; Drug: Oxaliplatin; Drug: Trastuzumab; Drug: Pembolizumab; Drug: Cisplatin; Drug: Fluorouracil

Interventions

KN026 DRUG

In accordance with the protocol

Experimental group: Combination of KN026 and CAPOX/PF with or without enlonstobart; Group A：Combination of KN026 and CAPOX/PF with or without enlonstobart

Capecitabine DRUG

Capecitabine is for oral administration.

Control group：Combination of trastuzumab and CAPOX/PF with or without Pembrolizumab; Experimental group: Combination of KN026 and CAPOX/PF with or without enlonstobart; Group A：Combination of KN026 and CAPOX/PF with or without enlonstobart; Group B: Combination of trastuzumab, and CAPOX/PF with or without enlonstobart

Enlonstobart DRUG

Enlonstobart is administered by intravenous infusion.

Experimental group: Combination of KN026 and CAPOX/PF with or without enlonstobart; Group A：Combination of KN026 and CAPOX/PF with or without enlonstobart; Group B: Combination of trastuzumab, and CAPOX/PF with or without enlonstobart

Oxaliplatin DRUG

Oxaliplatin is administered by intravenous infusion.

Control group：Combination of trastuzumab and CAPOX/PF with or without Pembrolizumab; Experimental group: Combination of KN026 and CAPOX/PF with or without enlonstobart; Group A：Combination of KN026 and CAPOX/PF with or without enlonstobart; Group B: Combination of trastuzumab, and CAPOX/PF with or without enlonstobart

Trastuzumab DRUG

Trastuzumab is administered by intravenous infusion.

Control group：Combination of trastuzumab and CAPOX/PF with or without Pembrolizumab; Group B: Combination of trastuzumab, and CAPOX/PF with or without enlonstobart

Pembolizumab DRUG

Pembolizumab is administered by intravenous infusion.

Control group：Combination of trastuzumab and CAPOX/PF with or without Pembrolizumab

Cisplatin DRUG

Cisplatin is administered by intravenous infusion.

Control group：Combination of trastuzumab and CAPOX/PF with or without Pembrolizumab; Experimental group: Combination of KN026 and CAPOX/PF with or without enlonstobart; Group A：Combination of KN026 and CAPOX/PF with or without enlonstobart; Group B: Combination of trastuzumab, and CAPOX/PF with or without enlonstobart

Fluorouracil DRUG

Fluorouracil is administered by intravenous infusion.

Control group：Combination of trastuzumab and CAPOX/PF with or without Pembrolizumab; Experimental group: Combination of KN026 and CAPOX/PF with or without enlonstobart; Group A：Combination of KN026 and CAPOX/PF with or without enlonstobart; Group B: Combination of trastuzumab, and CAPOX/PF with or without enlonstobart

Eligibility Criteria

• Age: 18 Years+
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age≥18 years old.
• Histologically or cytologically confirmed diagnosis of gastric cancer.
• Participants unresectable locally advanced or metastatic gastric cancer who had not received systemic treatment (participants who had progressed 6 months after prior neoadjuvant/adjuvant therapy could be enrolled).
• Confirmed to be HER2 positive (HER2-positive is defined as IHC 3+ or IHC 2+ with ISH positive) and PD-L1 status (participants of phase III should be confirmed by the pathology department of participating study center).
• Phase II: Presence of at least 1 measurable lesion per RECIST 1.1. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. Phase III:Presence of at least 1 evaluable lesion per RECIST 1.1. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
• ECOG PS of 0 - 1.
• Expected survival ≥ 3 months.
• Participants with adequate organ functions.
• Female and male participants of childbearing age agree to take adequate contraceptive measures during and upon completion of the study for 7 months after the last dose. Female participants of childbearing age must have a negative blood pregnancy test within 7 days before randomization.
• Voluntarily agree to participate in the study and sign the informed consent.

You may not qualify if:

• Has received anti-tumor treatment such as systemic chemotherapy or other trial interventions within 28 days, or immunotherapy (e.g. interleukin, interferon, thymospipeptide, etc.), hormone therapy or targeted therapy within 14 days or 5 half-life (whichever is shorter) before randomization.
• Participants with brain metastasis or spinal cord compression at screening (except for completed local treatment and discontinued glucocorticoids for at least 4 weeks before randomization , and stable central nervous system imaging and brain metastasis symptoms for at least 4 weeks).
• Participants with PD-L1 CPS ≥1, who are receiving long-term immunotherapy (e.g., cyclosporine) or require daily systemic steroid therapy (e.g., \>20 mg prednisone or equivalent), except those who treated with local glucocorticoids using nasal spray, inhalation, or other pathways.
• Participants with PD-L1CPS ≥1, who have an active autoimmune disease or have a history of autoimmune disease 2 years before randomization and still require systemic treatment. However, participant with the following diseases is allowed to enroll: well-controlled type I diabetes, well-controlled hypothyroidism that requires hormone replacement therapy, skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, or hair loss), or participant who is expected to not recur without external triggers.
• Participate in another clinical trial, unless it is an observational (non-intervention) clinical trial or is in the follow-up period of an intervention trial.
• Participants who have undergone major surgery or had invasive intervention within 28 days before randomization. Or those who plan to undergo systematic or local tumor resection during the trial .
• Any Chinese patent medicine with anti-cancer activity approved by the National Drug Administration (regardless of cancer type) has been used within 14 days before randomization.
• Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product.
• Active bacterial, fungal or viral infection before randomization. Participant who has recieved preventive infection treatment but has no clinical manifestations before randomization could be considered to enroll.
• Has a history of immunodeficiency, including HIV-positive.
• Active hepatitis B or C infection. Participant with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) need to test Hepatitis B virus DeoxyriboNucleic Acid (HBV-DNA), and HBV-DNA is higher than 500 IU/mL (or 2500 copies/ml) ; Participants with positive for hepatitis C (HCV) antibody and whose Hepatitis C virus Ribonucleic Acid (HCV-RNA) is higher than 1000 copies/ml or UNL (whichever is lower).
• Has a history of tuberculosis treatment within 2 years before randomization.
• Has activity or a history of interstitial lung disease at any stage and/or pulmonary function injury, a history of interstitial pneumonia requiring hormone therapy, or the imaging cannot rule out suspected interstitial lung disease/pneumonia at screening.
• Known to have low activity or lack of dihydropyrimidine dehydrogenase (DPD).
• Participants with peripheral neuropathy of grade \> 1.

Sponsors & Collaborators

• Shanghai JMT-Bio Inc.: lead

MeSH Terms

Interventions

Capecitabine; Oxaliplatin; Trastuzumab; Cisplatin; Fluorouracil

Intervention Hierarchy (Ancestors)

Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Uracil; Pyrimidinones; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Coordination Complexes; Organic Chemicals; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: This is an open-label, randomized, controlled, multi-center Phase II/III clinical study.

Study Record Dates

• First Submitted: December 25, 2025
• First Posted: January 12, 2026
• Study Start: December 30, 2025
• Primary Completion (Estimated): June 30, 2032
• Study Completion (Estimated): December 31, 2032
• Last Updated: January 12, 2026

Record last verified: 2025-12